Published August 15, 2017 | Version v1
Journal article

Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

  • 1. Liver Cancer Clinic, Gangnam Severance Hospital, Seoul (Korea, Republic of)
  • 2. Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonjuro, Gangnamgu, Seoul, 06723 (Korea, Republic of)
  • 3. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul (Korea, Republic of)
  • 4. Department of Radiology, Yonsei University College of Medicine, Seoul (Korea, Republic of)
  • 5. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul (Korea, Republic of)

Description

Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively. During CCRT, 5-fluorouracil (5-FU) was infused via chemoport during the first and last five days of five weeks of external beam radiation therapy. After CCRT, repeated HAIC with cisplatin and 5-FU was performed monthly. Nineteen patients (50%) underwent additional TACE between repeated HAICs. Factors related to overall survival and progression free survival (PFS) were analyzed. The mean age of patients was 55 years (male:female, 33:5). Underlying liver diseases were hepatitis B, hepatitis C and non-B/C in 29, 1 and 8 patients, respectively. The median radiation dose was 4500 cGy. The objective response (OR) rate at one months after CCRT was 36.8%. The median PFS was 7.4 (range, 1.8 − 32.1) months. The median overall survival was 11.6 (range 2.8-65.7) months. Achieving an OR after CCRT (hazard ratio [HR], 0.028; P < 0.001), additional TACE (HR, 0.134, P < 0.001), and further rounds of HAIC (HR, 0.742, P = 0.001) were independent significant factors related to overall survival. The overall survival duration of patients with an OR after CCRT (median 44.2 vs. 6.6 months, P < 0.001) and additional TACE (median 19.8 vs. 9.1 months, P = 0.001) were significantly greater than those without an OR after CCRT or additional TACE. Patients who achieved an OR after CCRT, underwent additional TACE, and were subjected to repeated rounds of HAIC following CCRT showed better survival after CCRT for advanced stage of HCC with vascular invasion. A further prospective study is needed to confirm the positive effect of additional TACE after CCRT. The online version of this article (doi:10.1186/s13014-017-0873-1) contains supplementary material, which is available to authorized users.

Availability note (English)

Available from http://dx.doi.org/10.1186/s13014-017-0873-1; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558652

Additional details

Identifiers

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
12
Journal Page Range
vp.
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
49082436
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; CHEMOTHERAPY; COMBINED THERAPY; EXTERNAL BEAM RADIATION THERAPY; FLUORINE COMPOUNDS; LIVER; PATIENTS; RADIATION DOSES
Descriptors DEC
BODY; DIGESTIVE SYSTEM; DISEASES; DOSES; GLANDS; HALOGEN COMPOUNDS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RADIOTHERAPY; THERAPY

Optional Information

Copyright
Copyright (c) The Author(s). 2017
Notes
PMCID: PMC5558652; PMID: 28810886; PUBLISHER-ID: 873; OAI: oai:pubmedcentral.nih.gov:5558652